Update: 21.01.2024
Last week: 1 week 2024 (30.12.2024 - 05.01.2025)
Last full month: December 2024
| Time period | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | |||||||||
| WoW | 5 794 | -27.4% | 13.8% | 1.4 | 11 428 439 | -26.1% | 9.9% | 1.2 | -34.8% |
| MoM | 39 753 | -10.9% | 13.5% | 0.2 | 76 154 633 | -3.6% | 9.5% | 0.5 | -12.4% |
| YTD | 5 794 | 43.3% | 13.8% | 3.6 | 11 428 439 | 31.2% | 9.9% | 1.3 | 5.8% |
| MAT | 423 197 | 24.0% | 12.4% | 3.2 | 841 803 537 | 27.7% | 9.3% | 1.6 | -8.1% |
| BRAINMAX | |||||||||
| WoW | 1 342 | -40.2% | 100.0% | 0 | 4 651 709 | -37.7% | 100.0% | 0 | -40.2% |
| MoM | 10 252 | -12.4% | 100.0% | 0 | 35 144 895 | -9.6% | 100.0% | 0 | -12.4% |
| YTD | 1 342 | 55.9% | 100.0% | 0 | 4 651 709 | 57.3% | 100.0% | 0 | 55.9% |
| MAT | 83 147 | 76.1% | 100.0% | 0 | 288 416 066 | 77.0% | 100.0% | 0 | 76.1% |
| GOLDLINE PLUS | |||||||||
| WoW | 9 467 | -32.9% | 45.7% | -1.6 | 30 196 962 | -33.2% | 37.8% | -0.9 | -30.6% |
| MoM | 59 737 | -4.8% | 46.6% | -0.8 | 189 099 862 | -3.4% | 37.9% | -0.8 | -3.1% |
| YTD | 9 467 | -23.2% | 45.7% | 0.6 | 30 196 962 | -29.4% | 37.8% | -0.5 | -24.2% |
| MAT | 826 243 | -5.1% | 45.4% | 0.5 | 2 590 231 313 | -4.1% | 37.1% | -2.5 | -6.1% |
| MIGRENIUM | |||||||||
| WoW | 6 783 | -25.1% | 0.4% | 0 | 2 370 703 | -25.0% | 0.5% | 0 | -23.7% |
| MoM | 36 820 | -10.5% | 0.4% | -0.1 | 12 854 774 | -8.7% | 0.5% | -0.1 | 5.1% |
| YTD | 6 783 | -13.9% | 0.4% | 0 | 2 370 703 | 24.0% | 0.5% | 0.1 | -6.6% |
| MAT | 566 749 | -11.4% | 0.5% | -0.1 | 182 110 334 | 48.3% | 0.6% | 0.2 | 3.3% |
| MODELAX-N | |||||||||
| WoW | 23 970 | -10.1% | 20.3% | 2 | 12 112 961 | -11.8% | 14.0% | 1.2 | -19.2% |
| MoM | 116 997 | -2.5% | 18.7% | -1.9 | 59 395 533 | -0.1% | 13.0% | -0.8 | 7.3% |
| YTD | 23 970 | 23.7% | 20.3% | 4.6 | 12 112 961 | 63.4% | 14.0% | 5.1 | -4.4% |
| MAT | 1 468 145 | 25.0% | 21.8% | 3.2 | 663 965 366 | 72.1% | 14.2% | 3.9 | 6.9% |
| REDUXIN | |||||||||
| WoW | 6 615 | -28.3% | 31.9% | 1 | 34 818 475 | -31.3% | 43.6% | 0.2 | -30.6% |
| MoM | 40 558 | -3.1% | 31.6% | 0 | 218 912 186 | -1.4% | 43.9% | 0 | -3.1% |
| YTD | 6 615 | -28.1% | 31.9% | -1.7 | 34 818 475 | -32.4% | 43.6% | -2.6 | -24.2% |
| MAT | 592 894 | -7.1% | 32.6% | -0.3 | 3 146 684 756 | 8.9% | 45.1% | 2.7 | -6.1% |
| REDUXIN FORTE | |||||||||
| WoW | 2 001 | -26.4% | 9.7% | 0.6 | 8 833 887 | -28.5% | 11.1% | 0.5 | -30.6% |
| MoM | 12 480 | -1.0% | 9.7% | 0.2 | 55 829 134 | 4.2% | 11.2% | 0.6 | -3.1% |
| YTD | 2 001 | -7.5% | 9.7% | 1.7 | 8 833 887 | -5.4% | 11.1% | 2.7 | -24.2% |
| MAT | 167 193 | 0.6% | 9.2% | 0.6 | 721 202 088 | 10.1% | 10.3% | 0.7 | -6.1% |
| SALVISAR | |||||||||
| WoW | 10 963 | -19.1% | 2.0% | 0.2 | 4 930 826 | -19.8% | 1.8% | 0.1 | -26.4% |
| MoM | 57 672 | -11.6% | 1.8% | -0.2 | 26 098 698 | -10.0% | 1.7% | -0.1 | -3.0% |
| YTD | 10 963 | 52.9% | 2.0% | 0.9 | 4 930 826 | 106.9% | 1.8% | 0.9 | -12.6% |
| MAT | 575 575 | 15.8% | 1.5% | 0.3 | 243 488 060 | 49.1% | 1.3% | 0.3 | -4.3% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 5 794 | 43.3% | 13.8% | 3.6 | 11 428 439 | 31.2% | 9.9% | 1.3 | 5.8% |
| BRAINMAX | 1 342 | 55.9% | 100.0% | 0 | 4 651 709 | 57.3% | 100.0% | 0 | 55.9% |
| GOLDLINE PLUS | 9 467 | -23.2% | 45.7% | 0.6 | 30 196 962 | -29.4% | 37.8% | -0.5 | -24.2% |
| MIGRENIUM | 6 783 | -13.9% | 0.4% | 0 | 2 370 703 | 24.0% | 0.5% | 0.1 | -6.6% |
| MODELAX-N | 23 970 | 23.7% | 20.3% | 4.6 | 12 112 961 | 63.4% | 14.0% | 5.1 | -4.4% |
| REDUXIN CAPS | 6 615 | -28.1% | 31.9% | -1.7 | 34 818 475 | -32.4% | 43.6% | -2.6 | -24.2% |
| REDUXIN FORTE | 2 001 | -7.5% | 9.7% | 1.7 | 8 833 887 | -5.4% | 11.1% | 2.7 | -24.2% |
| SALVISAR | 10 963 | 52.9% | 2.0% | 0.9 | 4 930 826 | 106.9% | 1.8% | 0.9 | -12.6% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 423 197 | 24.0% | 12.4% | 3.2 | 841 803 537 | 27.7% | 9.3% | 1.6 | -8.1% |
| BRAINMAX | 83 147 | 76.1% | 100.0% | 0 | 288 416 066 | 77.0% | 100.0% | 0 | 76.1% |
| GOLDLINE PLUS | 826 243 | -5.1% | 45.4% | 0.5 | 2 590 231 313 | -4.1% | 37.1% | -2.5 | -6.1% |
| MIGRENIUM | 566 749 | -11.4% | 0.5% | -0.1 | 182 110 334 | 48.3% | 0.6% | 0.2 | 3.3% |
| MODELAX-N | 1 468 145 | 25.0% | 21.8% | 3.2 | 663 965 366 | 72.1% | 14.2% | 3.9 | 6.9% |
| REDUXIN CAPS | 592 894 | -7.1% | 32.6% | -0.3 | 3 146 684 756 | 8.9% | 45.1% | 2.7 | -6.1% |
| REDUXIN FORTE | 167 193 | 0.6% | 9.2% | 0.6 | 721 202 088 | 10.1% | 10.3% | 0.7 | -6.1% |
| SALVISAR | 575 575 | 15.8% | 1.5% | 0.3 | 243 488 060 | 49.1% | 1.3% | 0.3 | -4.3% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 5 794 | -27.4% | 13.8% | 1.4 | 11 428 439 | -26.1% | 9.9% | 1.2 | -34.8% |
| BRAINMAX | 1 342 | -40.2% | 100.0% | 0 | 4 651 709 | -37.7% | 100.0% | 0 | -40.2% |
| GOLDLINE PLUS | 9 467 | -32.9% | 45.7% | -1.6 | 30 196 962 | -33.2% | 37.8% | -0.9 | -30.6% |
| MIGRENIUM | 6 783 | -25.1% | 0.4% | 0 | 2 370 703 | -25.0% | 0.5% | 0 | -23.7% |
| MODELAX-N | 23 970 | -10.1% | 20.3% | 2 | 12 112 961 | -11.8% | 14.0% | 1.2 | -19.2% |
| REDUXIN CAPS | 6 615 | -28.3% | 31.9% | 1 | 34 818 475 | -31.3% | 43.6% | 0.2 | -30.6% |
| REDUXIN FORTE | 2 001 | -26.4% | 9.7% | 0.6 | 8 833 887 | -28.5% | 11.1% | 0.5 | -30.6% |
| SALVISAR | 10 963 | -19.1% | 2.0% | 0.2 | 4 930 826 | -19.8% | 1.8% | 0.1 | -26.4% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 39 753 | -10.9% | 13.5% | 0.2 | 76 154 633 | -3.6% | 9.5% | 0.5 | -12.4% |
| BRAINMAX | 10 252 | -12.4% | 100.0% | 0 | 35 144 895 | -9.6% | 100.0% | 0 | -12.4% |
| GOLDLINE PLUS | 59 737 | -4.8% | 46.6% | -0.8 | 189 099 862 | -3.4% | 37.9% | -0.8 | -3.1% |
| MIGRENIUM | 36 820 | -10.5% | 0.4% | -0.1 | 12 854 774 | -8.7% | 0.5% | -0.1 | 5.1% |
| MODELAX-N | 116 997 | -2.5% | 18.7% | -1.9 | 59 395 533 | -0.1% | 13.0% | -0.8 | 7.3% |
| REDUXIN CAPS | 40 558 | -3.1% | 31.6% | 0 | 218 912 186 | -1.4% | 43.9% | 0 | -3.1% |
| REDUXIN FORTE | 12 480 | -1.0% | 9.7% | 0.2 | 55 829 134 | 4.2% | 11.2% | 0.6 | -3.1% |
| SALVISAR | 57 672 | -11.6% | 1.8% | -0.2 | 26 098 698 | -10.0% | 1.7% | -0.1 | -3.0% |
ОБОЗНАЧЕНИЯ
WoW - Week Over Week - показатели для сравнения результатов текущей и предыдущей недели
MoM - Month Over Month - показатели для сравнения результатов последнего полного месяца и предыдущего полного месяца
YTD - Year to Date - показатели для сравнения результатов за период времени, начинающийся с первого дня текущего календарного года до текущей даты с результатами за сопоставимый период прошлого года
MAT - Moving Annual Total - показатели для сравнения результатов за период 12 месяцев, с датой окончания на последней доступной неделе, с результатами за сопоставимый период прошлого года
MS - Market Share - Доля рынка = (Продажи бренда / Продажи категории)*100%
Change, % = (Продажи бренда за последний период / Продажи бренда за предыдущий период - 1)*100%
Change, p.p. = Доля бренда на рынке за последний период - Доля бренда на рынке за предыдущий период (выражается в процентных пунктах)
Cat. Volume Change, % = (Продажи категории в упаковках за последний период / Продажи категории в упаковках за предыдущий период - 1)*100%
Каждая категория собрана специально для каждого бренда и включает в себя бренд и его конкурентов
Список конкурентов можно найти в разделе "MS of competitors" в блоке каждого бренда
ABBREVIATIONS
WoW - Week Over Week - indicators for comparing the results of the current and previous week
MoM - Month Over Month - indicators for comparing the results of the* last full month* and previous full month
YTD - Year to Date - indicators for comparing the results of the period of time beginning the first day of the current calendar year up to the current date with the results of the comparable period last year
MAT - Moving Annual Total - indicators for comparing the results of the period, being 12 month period ending on the last week with the results of the comparable period last year
MS - Market Share - (Brand Sales / Category Sales)*100%
Change, % = (Brand Sales of the last period / Brand Sales of the previous period - 1)*100%
Change, p.p. = Brand Market Share of the last period - Brand Market Share of the previous period (expressed in percentage points)
Cat. Volume Change, % = (Category Sales in packs of the last period / Category Sales in packs of the previous period - 1)*100%
Each category is created specifically for each brand and includes the brand and its competitors
The list of competitors can be found in the subsection "MS of competitors" in sections for each brand
## [1] "MODELAX-N"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #2"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #4"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #8"
## [1] "MODELAX-N"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #2"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #4"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #8"
## [1] "AMBENE BIO"
## [1] "AMBENE BIO SOL FOR INJ 1 ML #10"
## [1] "AMBENE BIO SOL FOR INJ 2 ML #5"
## [1] "AMBENE BIO"
## [1] "AMBENE BIO SOL FOR INJ 1 ML #10"
## [1] "AMBENE BIO SOL FOR INJ 2 ML #5"
## [1] "MIGRENIUM"
## [1] "MIGRENIUM COATED TABLETS 65 MG+500 MG #20"
## [1] "MIGRENIUM"
## [1] "MIGRENIUM COATED TABLETS 65 MG+500 MG #20"
## [1] "SALVISAR"
## [1] "SALVISAR UNGUENT FOR EXT USE 100 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #2"
## [1] "SALVISAR UNGUENT FOR EXT USE 50 G #1"
## [1] "SALVISAR"
## [1] "SALVISAR UNGUENT FOR EXT USE 100 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #2"
## [1] "SALVISAR UNGUENT FOR EXT USE 50 G #1"
## [1] "REDUXIN CAPS"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #10"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #30"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #30"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #60"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #90"
## [1] "REDUXIN CAPS"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #10"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #30"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #90"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #10"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #30"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #60"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #90"
## [1] "REDUXIN FORTE"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #30"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #60"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #90"
## [1] "REDUXIN FORTE"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #30"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #60"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #30"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #60"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #90"
## [1] "GOLDLINE PLUS"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #10"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #90"
## [1] "GOLDLINE PLUS"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #10"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #90"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #10"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #90"
## [1] "BRAINMAX"
## [1] "BRAINMAX CAPS 250 MG+250 MG #20"
## [1] "BRAINMAX CAPS 250 MG+250 MG #40"
## [1] "BRAINMAX CAPS 250 MG+250 MG #60"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 2,5 ML #10"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 5 ML #10"
*****
## [1] "BRAINMAX"
## [1] "BRAINMAX CAPS 250 MG+250 MG #20"
## [1] "BRAINMAX CAPS 250 MG+250 MG #40"
## [1] "BRAINMAX CAPS 250 MG+250 MG #60"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 2,5 ML #10"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 5 ML #10"
[RUS] ОБОЗНАЧЕНИЯ
WoW - Week Over Week - показатели для сравнения результатов текущей и предыдущей недели
MoM - Month Over Month - показатели для сравнения результатов последнего полного месяца и предыдущего полного месяца
YTD - Year to Date - показатели для сравнения результатов за период времени, начинающийся с первого дня текущего календарного года до текущей даты с результатами за сопоставимый период прошлого года
MAT - Moving Annual Total - показатели для сравнения результатов за период 12 месяцев, с датой окончания на последней доступной неделе, с результатами за сопоставимый период прошлого года
MS - Market Share - Доля рынка = (Продажи бренда / Продажи категории)*100%
Change, % = (Продажи бренда за последний период / Продажи бренда за предыдущий период - 1)*100%
Change, p.p. = Доля бренда на рынке за последний период - Доля бренда на рынке за предыдущий период (выражается в процентных пунктах)
Cat. Volume Change, % = (Продажи категории в упаковках за последний период / Продажи категории в упаковках за предыдущий период - 1)*100%
Каждая категория собрана специально для каждого бренда и включает в себя бренд и его конкурентов
Список конкурентов можно найти в разделе "MS of competitors" в блоке каждого бренда
[ENG] ABBREVIATIONS
WoW - Week Over Week - indicators for comparing the results of the current and previous week
MoM - Month Over Month - indicators for comparing the results of the last full month and previous full month
YTD - Year to Date - indicators for comparing the results of the period of time beginning the first day of the current calendar year up to the current date with the results of the comparable period last year
MAT - Moving Annual Total - indicators for comparing the results of the period, being 12 month period ending on the last week with the results of the comparable period last year
MS - Market Share - (Brand Sales / Category Sales)*100%
Change, % = (Brand Sales of the last period / Brand Sales of the previous period - 1)*100%
Change, p.p. = Brand Market Share of the last period - Brand Market Share of the previous period (expressed in percentage points)
Cat. Volume Change, % = (Category Sales in packs of the last period / Category Sales in packs of the previous period - 1)*100%
Each category is created specifically for each brand and includes the brand and its competitors
The list of competitors can be found in the subsection "MS of competitors" in sections for each brand
DATA SOURCES:
DSM: Sales
Palomars: TRPs